Last reviewed · How we verify
Zactran (GAMITHROMYCIN)
Gamithromycin (Zactran) is a marketed antibiotic that inhibits bacterial protein synthesis, currently holding a position in the veterinary pharmaceutical market. A key strength of Zactran is its mechanism of action, which effectively targets bacterial protein synthesis, providing a robust therapeutic option. The primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | GAMITHROMYCIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
- Injection site swelling
- Transient animal discomfort